Petros Pharmaceuticals (PTPI) Stock Statistics & Valuation Metrics

Petros Pharmaceuticals has a market cap or net worth of $950.38K. The enterprise value is ―.

Petros Pharmaceuticals has 31,160,086 shares outstanding. The number of shares has decreased by -2.65% in one year.

Petros Pharmaceuticals’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -56.02%.

The current PE Ratio of Petros Pharmaceuticals is -0.38. Petros Pharmaceuticals’s PEG ratio is >-0.01.

In the last 12 months, Petros Pharmaceuticals had revenue of 5.82M and earned -8.16M in profits. Earnings per share was -6.35.

In the last 12 months, operating cash flow was -5.83M and capital expenditures -19.14K, giving a free cash flow of -5.85M billion.

Petros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Petros Pharmaceuticals upcoming earnings date is Nov 14, 2023, TBA Not Confirmed.

Petros Pharmaceuticals as a current ratio of 1.89, with Debt / Equity ratio of 232.54%

In the past 12 months, Petros Pharmaceuticals has paid 0.00 in taxes.

Petros Pharmaceuticals EV to EBITDA ratio is 0.47, with an EV/FCF ratio of 0.26.

Petros Pharmaceuticals has $3.89M in cash and marketable securities with $7.25M in debt, giving a net cash position of $3.35M billion.

Gross margin is 72.50%, with operating margin of -233.88%, and net profit margin of -140.20%.

The average price target for Petros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy